These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1752535)

  • 1. [Essential thrombocythemia: antiaggregants].
    Cortelazzo S; Barbui T
    Haematologica; 1991 Jun; 76 Suppl 3():371-3. PubMed ID: 1752535
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Passamonti F; Cazzola M
    Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose aspirin in polycythemia vera.
    Dutrillaux F; Maynadié M; Carli PM
    N Engl J Med; 2004 Apr; 350(16):1683-5; author reply 1683-5. PubMed ID: 15088322
    [No Abstract]   [Full Text] [Related]  

  • 5. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemorrhagic and thrombotic complications in polycythemia vera. A clinical study.
    Orlandi E; Castelli G; Brusamolino E; Canevari A; Morra E; Lazzarino M; Bernasconi C
    Haematologica; 1989; 74(1):45-9. PubMed ID: 2498182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
    Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
    Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry.
    Robier C; Neubauer M; Sternad H; Quehenberger F; Rainer F; Neumeister P
    Thromb Res; 2010 Sep; 126(3):232-7. PubMed ID: 20630570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
    Jurgens DJ; Moreno-Aspitia A; Tefferi A
    Haematologica; 2004 Nov; 89(11):1394-5. PubMed ID: 15531464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and diagnostic value of endogenous erythroid colony formation in essential thrombocythemia.
    Ciaudo M; Hadjez JM; Teyssandier I; Coly E; Zittoun R; Marie JP
    Hematol Cell Ther; 1998 Aug; 40(4):171-4. PubMed ID: 9766922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 12. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
    Elliott MA; Tefferi A
    Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of megakaryocytic and erythroid colony formation and platelet function tests on the risk of thromboembolic and bleeding complications in essential thrombocythaemia.
    Niittyvuopio R; Juvonen E; Kekomäki R; Oksanen K; Anttila P; Ruutu T
    Eur J Haematol; 2004 Apr; 72(4):245-51. PubMed ID: 15089761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
    Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
    Landolfi R; Di Gennaro L; Novarese L; Patrono C
    Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid].
    Fröhli P; Graf C; Rhyner K
    Schweiz Med Wochenschr; 1983 Nov; 113(44):1622-7. PubMed ID: 6685916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Thioguanine treatment for polycythemia vera and essential thrombocythemia.
    Delfini C; Nicolini G; Durazzi SM; Bartolucci M; Lucarelli G
    Haematologica; 1987; 72(3):273-5. PubMed ID: 3114098
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.